Marksans Pharma’s arm gets UK MHRA approval for Cetirizine Dihydrochloride
Relonchem in the UK, has received Marketing Authorization for Cetirizine Dihydrochloride
Marksans Pharma’s wholly owned subsidiary -- Relonchem in the UK, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution.
Earlier, the company’s wholly owned subsidiary -- Marksans Pharma Inc had received the final approval for Abbreviated New Drug Application (ANDA) from United States Food and Drug Administration (USFDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
Marksans Pharma is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets.
